AJOONI BIOTECH LIMITED

Regd. Office: D-118, Industrial Area, Phase VII, Mohali-160055 (Pb.)
Corp Office: H.No 1769, Phase 3B2, Mohali-160059
Phone: 0172-5020758-69 Website: www.ajoonibiotech.com
E-mail: ajooni.biotech@gmail.com / info@ajoonibiotech.com
CIN: L85190PB2010PLC040162

January 30, 2026

To,
National Stock Exchange of India Ltd
Exchange Plaza, Plot no. C/1, G Block,
Bandra-Kurla Complex, Bandra (E)
Mumbai - 400051

Dear Sir / Madam,

SUB: Outcome of the Board Meeting held on Friday, January 30, 2026
SYMBOL: AJOONI

Pursuant to Regulation 30 and other applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of the Company at its meeting held today i.e. Friday, January 30, 2026, at 11:00 A.M. at the Corporate Office of the Company situated at House No. 1769, Phase 3B2, Mohali, Punjab, has inter-alia considered and approved / noted the following:

1. **Un-audited Financial Results**
   The Board considered and approved the Un-audited Financial Results of the Company for the quarter ended December 31, 2025, along with the Limited Review Report issued by the Statutory Auditors.

2. **Proposal of Merger / Amalgamation:** The Board discussed the proposal of merger/amalgamation of Healthy Biosciences Limited with Ajooni Biotech Limited and, in this regard, after due deliberations, the Board was of the view that additional information, internal evaluation, and preliminary consultations are required before taking the matter forward. Accordingly, with the consent of the Chair, the Board decided to defer the above agenda item to a subsequent Board Meeting, to be convened at an appropriate time.

The meeting of the Board of Directors commenced at 11:00 A.M. and concluded at 12 noon.

Thanking You,
Yours Truly,
For Ajooni Biotech Limited
SWATI VIJAN
Digitally signed by SWATI VIJAN
Date: 2026.01.30 12:05:24 +05'30'
Swati Vijan
Company Secretary
F13627

AJOONI BIOTECH LIMITED

Regd. Office: D-118, Industrial Area, Phase VII, Mohali-160055 (Pb.)
Corp Office: H.No 1769, Phase 3B2, Mohali-160059
Phone: 0172-5020758-69 Website: www.ajoonibiotech.com
E-mail: ajooni.biotech@gmail.com / info@ajoonibiotech.com
CIN: L85190PB2010PLC040162

January 30, 2026

To,
National Stock Exchange of India Ltd
Exchange Plaza, Plot no. C/1, G Block,
Bandra-Kurla Complex, Bandra (E)
Mumbai - 400051

Dear Sir / Madam,

SYMBOL: AJOONI

Sub.: Approval of Un-Audited Financial Results for the quarter ended December 31, 2025.

Dear Sir,

Pursuant to the Regulation 33 of the SEBI (Listing Obligation and Disclosures Requirements) Regulation, 2015, we wish to inform that the Board of Directors of the Company at their meeting held on Friday, January 30, 2026 at the Corporate Office of the company have considered and approved the un-Audited Financial Statements for the quarter ended on December 31, 2026. In these regards, we are enclosing herewith:

1. Un-Audited Financial Results for the quarter ended on December 31, 2026 as recommended by the Audit Committee.
2. Limited Review Report from the auditor for the quarter December 31, 2026.

You are requested to kindly take the same on record.

Thanking You,
Yours Truly,
For Ajooni Biotech Limited
SWATI VIJAN
Digitally signed by SWATI VIJAN
Date: 2026.01.30 12:05:39 +05'30'
Swati Vijan
Company Secretary
FCS13627

AJOONI BIOTECH LIMITED

CIN : L85190PB2010PLC040162

STATEMENT OF STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 31ST DECEMBER 2025(In Lakhs)

	PARTICULARS	QUARTER ENDED					Year Ended (Audited)
		31.12.2025	30.09.2025	31.12.2024	Period Ended (UnAudited)	Period Ended (UnAudited)	31.03.2025
					31.12.2025	31.12.2024	
I	**Income**						
	Revenue from operations	5,875.33	3,173.51	3,403.46	12,175.61	8,541.75	11,469.19
	Other income	32.10	14.75	38.63	111.39	73.26	206.90
	Total income from operations	**5,907.43**	**3,188.26**	**3,442.09**	**12,287.00**	**8,615.01**	**11,676.09**
II	**Expenses**						
	Cost of Material Consumed	4,832.50	2,493.10	2,924.11	9,889.77	7,456.33	9,715.42
	Change In Inventories	(14.31)	6.78	(24.21)	(11.71)	(23.52)	(12.65)
	Employee benefit expenses	119.30	111.00	89.13	329.51	216.72	275.73
	Finance costs	18.32	17.21	6.83	43.99	27.75	33.43
	Depreciation and amortization expenses	81.47	24.54	23.75	130.84	71.25	109.35
	Payment to NSE						
	Other expenses	634.42	412.26	321.50	1,442.78	624.74	1,121.88
	Total expenses	**5,671.70**	**3,064.89**	**3,341.11**	**11,825.18**	**8,373.27**	**11,243.16**
III	**Profit/(Loss) before exceptional items and tax**	**235.73**	**123.37**	**100.98**	**461.82**	**241.74**	**432.93**
IV	**Exceptional items**						
V	**Profit/(Loss) before tax**	**235.73**	**123.37**	**100.98**	**461.82**	**241.74**	**432.93**
VI	**Tax expenses**						
	a) Current tax	70.26	32.08	22.22	124.84	53.18	102.42
	b) Deferred tax	-0.67	1.92	5.74	(0.51)	5.74	6.70
	b) Mat Credit						
VII	**Net Profit/(Loss) for the period/year**	**164.80**	**93.21**	**73.02**	**337.49**	**182.82**	**337.21**
VIII	**Other comprehensive income (net of tax)**				-		
	loss:	**(36.91)**		**2.14**	**(36.91)**	**56.28**	**(26.10)**

AJOONI BIOTECH LTD. MOHALI

	Total other comprehensive income						(26.10)
IX	Total comprehensive income for the period/year (VII+VIII)	127.89	93.21	75.16	300.58	239.10	311.10
X	Paid-up equity share capital (face value of the share shall be indicated)	3,444.87	3,444.87	3,444.87	3,444.87	3,444.87	3,444.87
XI	Other equity (excluding revaluation reserve)	5,288.88	5,456.23	5,288.88	5,663.60	5,288.88	5,363.02
XII	EPS in Rs. (Face Value of Rs.2/- each)*				-		
	-Basic	0.10	0.08	0.04	0.20	0.07	0.20
	-Diluted	0.10	0.08	0.04	0.20	0.07	0.20

Notes:

1. The above results are as per Regulation 33 of the SEBI (LODR) Regulations, 2015 as amended and have been taken on record by Board of Directors at its meeting held on 21-01-2026 after being reviewed by the Audit Committee.

2. The company is having single segment in accordance with IND AS 108 "operating segments". and therefore segment reporting is not applicable to the Company.

3. Due to re-grouping of schedules, and as per applicability of IND-AS, there has been a difference in the figures as reported earlier.

For Ajooni Biotech Limited

AJOONI BIOTECH LTD. MOHALI

Jasjot Singh
Managing Director
DIN: 01937631

Place : Mohali
Date : 30.01.2026

AJOONI BIOTECH LIMITED

CIN : L85190PB2010PLC040162

Statement of Assets and Liabilities

For the Year ended on 31st December 2025

in Rs. (Lakhs)

PARTICULARS	31ST DECEMBER 2025	31ST MARCH 2025
I. ASSETS		
(1) Non - Current Assets		
a) Property, Plant and Equipment	2,157.14	1,093.31
b) Capital Work In Progress	130.51	29.29
c) Investment Property		-
d) Goodwill		-
e) Other Intangible Assets	38.95	47.93
f) Intangible Assets Under Development		-
g) Biological Assets other than Bearer Plants		-
h) Financial Assets		
(1) Investments	328.78	349.36
(2) Trade Receivables		-
(3) Loans		-
(4) Other Financial Assets	1,504.93	1,506.79
i) Deffered Tax Asset (net)	38.42	37.92
j) Other Non Current Asset	502.11	240.11
(2) Current Assets		
a) Inventories	2,494.59	2,398.69
b) Financial Assets		
(1) Investments		
(2) Trade Receivables	2,184.98	1,621.64
(3) Cash & Cash Equivalent	17.32	683.02
(4) Bank Balances other than (iii) above		
(5) Loans	1,959.16	1,330.65
(6) Other Financial Asset		27.37
c) Current Tax Assets (net)		-
d) Other Current Asset	16.15	139.03
TOTAL	11,373.04	9,505.11
II EQUITY AND LIABILITIES		
(1) Equity		
a)Equity Share Capital	3,444.87	3,444.87
b) Other Equity	5,663.60	5,363.02
(2) Non-Current Liabilities		
a) Financial Liabilities		
(1) Borrowings	167.40	193.97
(2) Trade Payables		
(3) Other Financial Liabilties		
b) Employee Benefit Obligations	10.14	21.13
c) Deferred Tax Liability (net)		-
d) Other Non Current Liability		-
(3) Current Liabilities		
a) Financial Liabilities		
(1) Borrowings	863.81	0.00
(2) Trade Payables	1,041.25	349.52
(3) Other Financial Liabilities		
b) Employee Benefit Obligations	22.07	0.93
c) Other Current Liabilities	35.06	29.25

AJOONI BIOTECH LTD. MOHALI

d) Current tax liabilities (Net)	124.84	102.42
TOTAL	11,373.04	9,505.11

Place : Mohali
Date : 30.01.2026

For Ajooni Biotech Limited

Jasjot Singh
Managing Director
DIN: 01937631

AJOONI BIOTECH LTD. MOHALI

NARINDER KUMAR AND COMPANY
CHARTERED ACCOUNTANTS

SCO 65-B (1st Floor) City Heart,
Kharar Chandigarh Road,
Kharar, SAS Nagar Mohali-140301
Mobile : 98154 50065
Email : nkgargca@yahoo.co.in

Ref. No. ..... Dated .....

Limited Review Report

Review Report to Board of Directors of M/s Ajooni Biotech Limited.

We have reviewed the accompanying statement of unaudited financial results of M/s Ajooni Biotech Limited having Regd. office at D-118, Industrial Area, Phase-VII, Mohali Punjab-160055. for the period ended 31st December, 2025.(the Statement) attached herewith , being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and disclosure requirements) regulations 2015 (as amended) , Including relevant circulars issued by the Securities and Exchange Board of India (SEBI) from time to Time.

This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, Engagements to Review Financial Statements issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For NARINDER KUMAR AND COMPANY
Chartered Accountants

NARINDER KUMAR & COMPANY
S.C.O. 65-B
(1st Floor) City Heart
Kharar-Chandigarh Road
Kharar, Mohali - 140301
FRN-0030737N
Chartered Accountants

(NARINDER KUMAR GARG)
PARTNER
M.NO-080287

Date:-30.01.2026

UDIN:- 26080287MPURJM8725SCA